

RECEIVED

FORM PTO-1449 (REV 7-80)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO 480102.408USPC	APPLICATION NO 09/913.373
INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		APPLICANTS Gregory N. Beatch et al.	
		FILING DATE August 13, 2001	GROUP ART UNIT Not yet assigned

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

JAN 15 2002
 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DAW	AA 4,145,435	03/20/79	Szmuszkovicz	424	274	
DAW	AB 4,880,800	11/14/89	Wallis et al.	514	211	
	AC					
	AD					
	AE					

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
DAW	AF	DE 2 259 260	06/06/74	GERMANY		X
DAW	AG	DE 3 517 901	12/12/85	GERMANY		X
DAW	AH	JP 02-270864	11/05/90	JAPAN		X
DAW	AI	WO 94/14435	07/07/94	WIPO		
DAW	AJ	WO 96/23894	08/08/96	WIPO		

OTHER PRIOR ART *(Including Author, Title, Date, Pertinent Pages, Etc.)*

DAW	AK	Crotti et al., "Regiochemical Control of the Ring-Opening of Epoxides by Means of Chelating Processes. Part 13. Synthesis and Ring-Opening Reactions of the Diastereoisomeric cis- and Transepoxydes Derived From 3-(benzyloxy)cyclopentene and 2-(benzyloxy)-2, 5-dihydrofuran," <i>Chemical Abstracts</i> 129(17):662-663, abstract no. 216472k, October 26, 1998. ✓
DAW	AL	Morisawa et al., "Preparation of Fluorocarbocyclic Nucleosides as Antitumor Agents." <i>Chemical Abstracts</i> 115(5):904-905, abstract no. 50215n, August 5, 1991. ✓
DAW	AM	Orth et al., "Cyclopentane-1-amines." <i>Chemical Abstracts</i> 89(15):555, abstract no. 129113f, October 9, 1978. ✓
DAW	AP	Abstract of DE 2 259 260, Derwent World Patents Index, June 6, 1974. ✓
DAW	AO	Abstract of JP 02-270864, espacenet database, November 5, 1990. ✓

EXAMINER Danya Wright	DATE CONSIDERED 4-24-03
------------------------------	--------------------------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).